Dupont Capital Management Corp lowered its stake in Blueprint Medicines Corp (NASDAQ:BPMC) by 53.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,725 shares of the biotechnology company’s stock after selling 6,560 shares during the quarter. Dupont Capital Management Corp’s holdings in Blueprint Medicines were worth $447,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in BPMC. Renaissance Technologies LLC acquired a new stake in Blueprint Medicines in the 2nd quarter valued at $15,603,000. Eagle Asset Management Inc. acquired a new stake in Blueprint Medicines during the 2nd quarter worth $8,559,000. Voya Investment Management LLC boosted its stake in Blueprint Medicines by 37.6% during the 2nd quarter. Voya Investment Management LLC now owns 436,894 shares of the biotechnology company’s stock worth $27,734,000 after purchasing an additional 119,406 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in Blueprint Medicines by 4.0% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,677,731 shares of the biotechnology company’s stock worth $106,503,000 after purchasing an additional 64,095 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Blueprint Medicines by 1.9% during the 2nd quarter. BlackRock Inc. now owns 3,321,905 shares of the biotechnology company’s stock worth $210,876,000 after purchasing an additional 63,392 shares during the last quarter.

In other news, insider Marion Dorsch sold 2,300 shares of Blueprint Medicines stock in a transaction on Monday, September 17th. The stock was sold at an average price of $70.47, for a total transaction of $162,081.00. Following the transaction, the insider now owns 2,300 shares in the company, valued at approximately $162,081. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction on Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the transaction, the chief executive officer now owns 20,000 shares in the company, valued at approximately $1,269,800. The disclosure for this sale can be found here. 3.15% of the stock is owned by insiders.

Shares of BPMC opened at $51.88 on Wednesday. Blueprint Medicines Corp has a 52-week low of $50.51 and a 52-week high of $109.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.05 and a current ratio of 10.05.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.87 million. During the same quarter in the prior year, the firm earned ($0.96) EPS. The firm’s revenue was down 86.4% on a year-over-year basis. Equities analysts expect that Blueprint Medicines Corp will post -5.25 earnings per share for the current fiscal year.

Several brokerages have issued reports on BPMC. BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Guggenheim began coverage on shares of Blueprint Medicines in a research note on Tuesday, September 18th. They set a “buy” rating and a $102.00 target price on the stock. ValuEngine cut shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 24th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Sunday, October 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $101.00 target price on shares of Blueprint Medicines in a research note on Monday, October 22nd. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Blueprint Medicines currently has an average rating of “Buy” and an average target price of $97.14.

TRADEMARK VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/11/21/blueprint-medicines-corp-bpmc-shares-sold-by-dupont-capital-management-corp.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Article: Cash Flow

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.